Advancing Nanomedicine: Next-Generation Drug Delivery for Cancer and Regenerative Therapy
A special issue of Bioengineering (ISSN 2306-5354). This special issue belongs to the section "Nanotechnology Applications in Bioengineering".
Deadline for manuscript submissions: 31 May 2024 | Viewed by 72
Special Issue Editors
Interests: extracellular vesicles for targeting tumor lesions and regenerative medicines; mRNA-based therapeutics; combination therapy in combating cancer; biomaterials for tissue engineering and regeneration
Special Issue Information
Dear Colleagues,
Recent advances in nanomedicines, including various nanoplatforms, explorations of new molecules, and the design of targeted and personalized strategies, have made major contributions to transforming current therapeutic paradigms in improving drug delivery efficiency for cancer treatment and regeneration. This Special Issue is dedicated to the development of new delivery platforms (e.g., lipid-based nanoparticle (LNP), extracellular vesicles (EVs), polymeric nanoparticles, etc.), advanced biopharmaceutical formulations, tissue-targeted delivery, and novel routes of administration, all with the aim of optimizing drug delivery efficiency. Additionally, the combination of these advancements with other therapies or tissue engineering strategies, which synergistically enhance treatment efficacy, will be highly involved. Our aim is to collect original research papers and review papers on the development of nanomedicine delivery systems and technologies that can carry active therapeutics for the treatment and regeneration of cancer and other diseases. Submissions covering basic, pre-clinical, and clinical research on the development of new or existing drug delivery systems and related therapies are welcome to be submitted to this Special Issue.
Dr. Yifan Ma
Dr. Sijin Wu
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Bioengineering is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- nanoplatform
- delivery system
- targeted drug delivery
- cancer therapy
- regeneration
